A strategy for finding new medicines against the novel coronavirus disease (COVID-19) derived from base pairing with DNA damages
<p>The spread of the novel coronavirus disease (COVID-19) has caused a global pandemic. Exiting agents that act on proteins including 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), helicase, RNA-dependent RNA polymerase (RdRp), spike glycoprotein (S protein), and others i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications,
2020-12-22.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>The spread of the novel coronavirus disease (COVID-19) has caused a global pandemic. Exiting agents that act on proteins including 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), helicase, RNA-dependent RNA polymerase (RdRp), spike glycoprotein (S protein), and others in similar viruses [1,2] are likely used as antiviral drugs against the novel coronavirus (SARS-CoV-2). Data on Chemical Abstract Service show that the potential drug candidates against 3CLpro and RdRp are more than those against other targets [2].</p><p><br></p> |
|---|---|
| DOI: | 10.17352/2455-5363.000038 |